Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Lenvatinib in Advanced Vulvar Cancer
NCT05903833Phase 2Recruiting
- Sponsor
- AGO Research
- Start
- Jun 2025
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in vulvar squamous cell carcinoma (VSCC), sponsored by AGO Research. Started Jun 2025; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT05903833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05903833.